Compare · ABT vs GENB
ABT vs GENB
Side-by-side comparison of Abbott Laboratories (ABT) and Generate Biomedicines Inc. (GENB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and GENB operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $190.62B, about 112.4x GENB ($1.70B).
- ABT has been more active in the news (11 items in the past 4 weeks vs 6 for GENB).
- ABT has more recent analyst coverage (25 ratings vs 6 for GENB).
- Company
- Abbott Laboratories
- Generate Biomedicines Inc.
- Price
- -
- -
- Market cap
- $190.62B
- $1.70B
- 1M return
- +9.26%
- -
- 1Y return
- -13.02%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- News (4w)
- 11
- 6
- Recent ratings
- 25
- 6
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Latest ABT
- Late-breaking one-year data show Abbott's next-generation Amulet 360™ device continues to demonstrate high rates of left atrial appendage closure and low incidence of stroke
- Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Lithotripsy System
- Abbott initiates pivotal trial for Cephea™ device, an innovative treatment for mitral heart valve disease
- Abbott Labs downgraded by Argus
- Abbott launches whole-genome sequencing Oncodetect® molecular residual disease (MRD) test to detect traces of cancer during and after treatment
- Abbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect® test in colorectal cancer
- Nasdaq and Small Caps Lead Three Day Surge as Crude Slides and Blue Chips Hold Firm
- SEC Form 8-K filed by Abbott Laboratories
- SEC Form 8-K filed by Abbott Laboratories
- Abbott Reports Third-Quarter 2026 Results and Reaffirms Full-Year EPS Guidance
Latest GENB
- 2027 Could Finally Be the Year Cancer Is on the Ropes!
- SEC Form 144 filed by Generate Biomedicines Inc.
- Generate Biomedicines to Participate in November Investor Conferences
- AI-Designed Biologics Are Moving From the Screen to the Bench, and Developers Are Hiring for the Next Test
- Generate Biomedicines and Zealand Pharma Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases
- Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases
- Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of ‘Armored’ CAR T Therapy for Ovarian Cancer
- Generate Biomedicines Inc. to Participate in September Investor Conferences
- Director Arnold Frances sold $16,002 worth of shares (1,000 units at $16.00) as part of a pre-agreed trading plan, decreasing direct ownership by 0.43% to 231,472 units (SEC Form 4)
- SEC Form 144 filed by Generate Biomedicines Inc.